Regeneron (REGN +5.8%) gains after blowing away Q3 estimates earlier this morning. Total...
Wednesday, October 24, 2012, 1:30 PM ETRegeneron (REGN +5.8%) gains after blowing away Q3 estimates earlier this morning. Total revenues soared over 300% Y/Y on strong demand for Eylea, REGN's injection for the treatment of neovascular age-related macular degeneration. Sales of the drug were up 26% from 2Q. The company boost its sales estimates again for the year, and notes that Eylea should further fuel growth in 2013 following recent FDA approval for its expanded use.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles